

**Evaluation Only. Created with Aspose.Words. Copyright 2003-2020 Aspose Pty Ltd.**

## **The Toll-Like Receptor 5 agonist flagellin prevents *Non-typeable Haemophilus influenzae*-induced exacerbations in cigarette smoke-exposed mice.**

**Magdiel Pérez-Cruz<sup>1#</sup>, Bachirou Koné<sup>1#</sup>, Rémi Porte<sup>1</sup>, Christophe Carnoy<sup>1</sup>, Julien Tabareau<sup>1</sup>, Pierre Gosset<sup>2</sup>, François Trottein<sup>1</sup>, Jean-Claude Sirard<sup>1</sup>, Muriel Pichavant<sup>1#</sup> and Philippe Gosset<sup>1#\*</sup>**

<sup>1</sup> Univ. Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, Institut Pasteur de Lille, CIIL - Center for Infection and Immunity of Lille, 59000 Lille, France.

<sup>2</sup> Service d'Anatomo-pathologie, Hôpital Saint Vincent de Paul, Lille, France.

# Equal contribution

**\*Correspondence:**

Philippe Gosset, PhD

E-mail: [philippe.gosset@pasteur-lille.fr](mailto:philippe.gosset@pasteur-lille.fr)

**Key words:** Chronic obstructive pulmonary disease; Toll-like receptor 5 agonist; Bacterial infection; Lung, IL-22.

**Short Title:** Flagellin protects against COPD exacerbations

**Word count:** 4273 Words

**Created with an evaluation copy of Aspose.Words. To discover the full versions of our APIs please visit: <https://products.aspose.com/words/>**

## Abstract

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. The major bacterial cause of COPD exacerbations is non-typeable *Haemophilus influenzae* (NTHi). This susceptibility to infection involves a defective production of interleukin (IL)-22 which plays an important role in mucosal defense. Prophylactic administration of flagellin, a Toll-like receptor 5 (TLR5) agonist, protects healthy mice against respiratory pathogenic bacteria. We hypothesized that TLR5-mediated stimulation of lung immunity might prevent COPD exacerbations due to NTHi. Mice were chronically exposed to cigarette smoke and then infected with NTHi. According our preventive or therapeutic protocol, flagellin was administered intraperitoneally. Cigarette smoke-exposed mice treated with flagellin showed a lower bacterial load in the airways, the lungs and the blood. This protection was associated with an early neutrophilia, a lower production of pro-inflammatory cytokines and an increased IL-22 production. Flagellin treatment decreased the recruitment of inflammatory cells and the lung damages related to exacerbation. Protective effect of flagellin against NTHi was altered by treatment with anti-IL-22 blocking antibodies in cigarette smoke-exposed mice and in *Il22*<sup>-/-</sup> mice. Flagellin treatment also amplified the production of the  $\beta$ -defensin2 anti-bacterial peptides. This study shows that stimulation of innate immunity by a TLR5 ligand is a potent antibacterial treatment in cigarette smoke exposed mice, suggesting innovative therapeutic strategies against acute exacerbation in COPD.

## Introduction

Chronic obstructive pulmonary disease (COPD) is characterized by a progressive and irreversible decline in lung function <sup>1</sup>. Being the third leading cause of death worldwide, it is mainly caused by chronic exposure to cigarette smoke (CS) or pollutants <sup>2</sup>. Inhalation of CS essentially leads to activation of epithelial cells and macrophages responsible for the mobilization of effector and immuno-modulatory cells including neutrophils and natural killer T (NKT) cells <sup>3, 4</sup>. The chronic inflammatory response progressively leads to airway remodeling, impaired mucociliary clearance and parenchymal destruction in the lungs, further culminating in irreversible airflow limitation <sup>5</sup>. These components are involved in the increased susceptibility of COPD patients to bacterial and viral airway infections.

Airway colonization with bacteria such as *Haemophilus influenzae*, *Streptococcus pneumoniae* and *Moraxella catarrhalis* contributes to the pathogenesis and clinical course of the disease <sup>6</sup>. This colonization is responsible for lung infection leading to exacerbations of the disease, which have a strong impact on health status, exercise capacity, lung function, and mortality. Non-typeable *Haemophilus influenzae* (NTHi), a Gram-negative coccobacillus that lacks a polysaccharide capsule, is an important cause of COPD exacerbations and comorbidity <sup>7, 8</sup>. Acute exacerbations invariably scarred the chronic course of COPD <sup>9</sup>. Bacterial infections are first controlled by the innate immune system, which implicated pathogen-associated molecular pattern (PAMP) recognition by Toll-like receptors (TLR) such as those recognizing flagellin (TLR5) responsible for the mobilization of effector cells <sup>10</sup>. During COPD, bacterial infection is characterized by an increased influx of immune cells, including neutrophils, macrophages, dendritic cells (DC) and T lymphocytes <sup>3, 11, 12</sup>. However, this response is not effective enough to clear the pathogens. In this context, we recently reported a defective production of IL-22 in response to bacteria both in COPD patients and mice chronically

exposed to CS, whereas IL-17 production is only altered after infection by *S. pneumoniae*<sup>13</sup>,<sup>14</sup>. Interestingly, the Th17 cytokines IL-17 and IL-22 promote the recruitment of neutrophils, the synthesis of antimicrobial peptides and the expression of tight junction molecules<sup>15, 16</sup>, a mechanism explaining the essential role of IL-22 in the clearance of NTHi<sup>17</sup>. Supplementation of COPD mice with recombinant IL-22 increases the clearance of the bacteria and prevents the development of COPD exacerbations in mice. Several reports showed that activation of innate receptors, including TLR, is able to elicit protective immune responses against infections<sup>18, 19</sup>. Among them, systemic administration of flagellin, the main component of bacterial flagella and the TLR5 ligand, induces immediate production of Th17 cytokines through the activation of DC and type 3 innate lymphoid cells<sup>20</sup>.

In this study, we hypothesized that systemic administration of flagellin could limit the development of NTHi-induced COPD through eliciting an appropriate protective IL-22 response. We reported here that systemic stimulation of the innate immunity by flagellin from *Salmonella enterica* serovar Typhimurium (FliC) could prevent COPD exacerbation induced by NTHi. We also showed that the protective effect of flagellin against NTHi was dependent of IL-22 and associated with the upregulation of anti-microbial peptides.

## Material and Methods

### Animals

Male C57BL/6 (WT) mice, 6–8 weeks old were purchased from Janvier Labs (Le Genest-St-Isle, France). *I122<sup>-/-</sup>* mice were obtained from Jean-Christophe Renault (Brussel, Belgium). WT mice were daily exposed to cigarette smoke (CS) during 12 weeks (5 cigarettes/day, 5 days / week) to mimic COPD pathogenesis<sup>4</sup>. 3R4F research cigarettes were obtained from the University of Kentucky Tobacco and Health Research Institute (Lexington, KY, USA). The control group was exposed to ambient air. After 12 weeks of CS or air exposure, mice were either treated intranasally with phosphate buffered saline (PBS) or NTHi (n=4 per group). *I122<sup>-/-</sup>* mice were infected or not with NTHi. Experiments were performed at least in triplicate. Mice were examined every working day and humane endpoints essentially based on an important weight loss of more than 20% were applied for each experiment. However, our protocols did not provoke such a situation. Mice were euthanized by cervical dislocation according to the French government guidelines of laboratory animal care and approved by the Departmental Direction of Veterinary Services (Prefecture of Lille, France), European guidelines of laboratory animal care (number 86/609/CEE) and French legislation (Government Act 87-848). The present project has been approved by the national Institutional Animal Care and Use Committee (CEEA 75) and received the authorization number APAFIS# 7281.

### Mice infection and flagellin treatment

NTHi 3224A strain was grown to log-phase in brain-heart infusion (BHI) broth (AES Laboratory) supplemented with 10µg/ml haematin and 10µg/ml nicotinamide adenine

dinucleotide (NAD) (SIGMA, St Louis, MI, USA), and stored at  $-80^{\circ}\text{C}$  in BHI 10% glycerol for up to 3 months.

Working stocks were thawed, washed with sterile PBS, and diluted to the appropriate concentration. Mice were anesthetized and intranasally (i.n.) infected with  $2.5 \times 10^6$  CFU of NTHi. The number of infectant bacteria was confirmed by plating serial dilutions onto chocolate agar plates.

To prepare heat-killed (HK) NTHi, bacteria were grown to a log-phase ( $\text{O.D}_{600\text{nm}}=0.7-0.8$  units) and inactivated for 1 hour at  $56^{\circ}\text{C}$  in a hot-water-bath. Broth cultures were then plated onto chocolate agar plates and incubated overnight to check bacterial inactivation.

Endotoxin-free flagellin was purified and depleted in endotoxin as described previously<sup>21</sup>. To evaluate the protective effect,  $5\mu\text{g}$  of flagellin was administered intraperitoneally (i.p.) just before bacterial challenge. For IL-22 neutralizing experiment, mice received  $200\mu\text{g}$  of neutralizing anti-IL-22 (AM22) or control isotype (a mouse IgG2a) antibodies intravenously 5 minutes before infection.

### **Sample collection and processing**

Mice were sacrificed 24h and 48h post-infection by NTHi. Broncho-alveolar Lavage (BAL) fluids, lungs, spleen and blood were collected and kept on ice till the processing or immediately frozen in liquid nitrogen.

BAL was performed by instilling  $5 \times 0.5$  ml of sterile PBS + 2% fetal bovine serum (FBS) via a 1 ml sterile syringe with 23-gauge lavage needle into a tracheal incision. BAL samples were used for cytokine analysis, flow cytometry analysis and numbering of CFU. Lung tissues were collected aseptically and analyzed for CFU counts, cytokines, pulmonary cell profiles (flow cytometry analysis and lung cell restimulation) and histology. Blood was used for the determination of CFU counts.

**Created with an evaluation copy of Aspose.Words. To discover the full versions of our APIs please visit: <https://products.aspose.com/words/>**

## Flow cytometry

Cells harvested from BAL and lungs were washed and incubated with antibodies (BD, Franklin lakes, NJ, USA) for 30 min. Staining was performed as previously reported by Sharan et al. <sup>14</sup>. Data were acquired on a LSR Fortessa (BD Biosciences) and analyzed with FlowJo™ software v7.6.5 (Stanford, CA, USA). Gating strategies are. Debris were excluded according to size (FSC) and granularity (SSC). Immune cells expressing CD45 were gated to analyse frequency, activation and number of cell subsets. Phenotypes are shown in the table 1.

Table 1: Phenotype of the major cell populations identified in this report.

Cell population	Phenotype
Alveolar Macrophages	F4/80 <sup>+</sup> CD11c <sup>+</sup> CD64 <sup>+</sup> SiglecF <sup>+</sup>
Neutrophils	F4/80 <sup>-</sup> CD11c <sup>-</sup> CD11b <sup>+</sup> Ly6G <sup>+</sup>
Dendritic cells	F4/80 <sup>-</sup> CD11c <sup>+</sup> I-Ab <sup>+</sup> CD64 <sup>-</sup>
Inflammatory monocytes	F4/80 <sup>+</sup> CD11c <sup>-</sup> Ly6G <sup>-</sup> Ly6C <sup>+</sup> CCR2 <sup>+</sup>
Conventional T cells	CD5 <sup>+</sup> TCRαβ <sup>+</sup> NK1.1 <sup>-</sup>
NKT like cells	NK1.1 <sup>+</sup> TCRαβ <sup>+</sup>

## Cytokine measurement

Levels of IFN- $\gamma$ , IL-1 $\beta$ , IL-6, IL-17, IL-22, IL-23 and tumor necrosis factor alpha (TNF- $\alpha$ ) were quantified in lung tissue lysates and BAL using commercial ELISA kits (Invitrogen, San Diego, USA; Biotechne, Minneapolis, USA) (Table 2). Similarly, levels of IFN- $\gamma$ , IL-17, and IL-22 were measured in the supernatants of dissociated lung cells ( $0.5 \times 10^6$  of cells) re-stimulated with HK NTHi or not during 72h.

**Table 2:** List of the antibodies and of the ELISA kits used in this study.

Flow cytometry mAb	Target	Manufacturer	Catalog Nb
	FITC- I-Ab	Miltenyi Biotech	130-102-168
	PE-F4/80	Miltenyi Biotech	130-102-422
	PerCP-Cy5.5 - CD103	BD Biosciences	563637

**Created with an evaluation copy of Aspose.Words. To discover the full versions of our APIs please visit: <https://products.aspose.com/words/>**

	PE-Cy7 - CD11c	BD Biosciences	558079
	APC - CCR2	Miltenyi Biotech	130-119-658
	AF700 - CD86	BD Biosciences	560581
	APC-H7- Ly6G	BD Biosciences	560600
	V450 - CD11b	BD Biosciences	560455
	VioGreen - CD45	Miltenyi Biotech	130-110-665
	BV605 - Ly6C	Biolegend	128036
	BV786 - CD64	BD Biosciences	741024
	PE-CF594 - SiglecF	BD Biosciences	562757
	FITC - CD5	Miltenyi Biotech	130-102-574
	Tetramer mCD1d 167ms	NIH facility	30663
	PerCP-Cy5.5 - NK1.1	Miltenyi Biotech	130-103-963
	PE-Cy7 - CD4	Miltenyi Biotech	130-102-411
	APC - CD25	Miltenyi Biotech	130-102-550
	AF700 - CD69	BD Biosciences	561238
	APC-Vio770 - TCR $\gamma\delta$	Miltenyi Biotech	130-104-016
	VioBlue -TCR $\beta$	Miltenyi Biotech	130-104-815
	V500 - CD8	BD Biosciences	130-109-252
	BV605 - CD45	Biolegend	103140
ELISA kits	Target	Manufacturer	Catalog Nb
	IFN- $\gamma$ ELISA kit	Invitrogen	88-7314-88
	IL-1 $\beta$ DuoSet	Biotechne	DY401
	IL-6 ELISA kit	Invitrogen	88-7064-88
	IL-17 ELISA kit	Invitrogen	88-7371-88
	IL-22 DuoSet	Biotechne	DY582
	IL-23 ELISA kit	Invitrogen	88-7230-88
	TNF- $\alpha$ ELISA kit	Invitrogen	88-7371-88

### RT-PCR quantification of mRNA expression

Quantitative RT-PCR was performed to quantify mRNA of interest (Table 3). Results were expressed as mean  $\pm$  SEM of the relative gene expression calculated for each experiment in folds ( $2^{-\Delta\Delta C_t}$ ) using *Gapdh* as a reference, and compared to non-infected PBS-treated control mice.

**Table 3: Primer sequences for qRT-PCR in mice.** Forward (F) and reverse (R) primers are cited.

**Created with an evaluation copy of Aspose.Words. To discover the full versions of our APIs please visit: <https://products.aspose.com/words/>**




<i>Genes</i>	<i>Sequences</i>	
<i>Gapdh</i>	F	TGCCCAGAACATCATCCCTG
	R	TCAGATCCACGACGGACACA

**This document was truncated here because it was created in the Evaluation Mode.**



**Created with an evaluation copy of Aspose.Words. To discover the full versions of our APIs please visit: <https://products.aspose.com/words/>**

# Figure 1



bioRxiv preprint doi: <https://doi.org/10.1101/2020.07.08.193128>; this version posted July 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.




Fig 2






Fig 3




Fig 4




Fig 5